$AVAH

Aveanna Healthcare Holdings, Inc. (AVAH): Results of Operations and Financial Condition

Aveanna Healthcare Holdings, Inc. (AVAH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 avah-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE • Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period • Second Quarter Net income was $40.3 m

Original reporting
Published Aug 13, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVAHBullishHigh
01

Why it matters

The key tradable update is the guidance increase for both revenue and Adjusted EBITDA, alongside improved quarterly revenue, net income, and operating cash flow/free cash flow figures.

02

Market read

Traders can update AVAH’s FY2026 expectations immediately using the raised revenue and Adjusted EBITDA targets disclosed in the filing.

03

What to watch

The company does not guide net income due to volatility from fair value adjustments tied to interest rate caps, which can complicate equity valuation versus EBITDA-focused expectations.

Relevance 7/10Novelty 9/10Timing: pre-market today (8-K filed Aug 13, 2026)

Background

This is an SEC Form 8-K reporting Aveanna’s Q2 2026 financial results and revised full-year 2026 guidance (year ending Jan 2, 2027).

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Aveanna reported Q2 results and raised FY2026 revenue guidance to greater than $2.68B and Adjusted EBITDA to greater than $365M.

Expected impact

Likely near-term positive bias as traders re-rate FY2026 growth and profitability expectations; watch for margin/guidance skepticism given gross margin as a % of revenue declined year over year.

Evidence & confidence

The filing is a primary disclosure (8-K with earnings exhibit) and includes explicit, time-bound guidance increases and quarterly financial datapoints.

Market effects

Home care operators may see read-across demand for preferred payor and government affairs execution if peers are similarly exposed to reimbursement dynamics.

Limited; company-specific guidance update rather than a broad regional macro shift.

Low; US-focused healthcare services guidance with no stated international drivers.

Counterpoint

Gross margin as a percent of revenue fell to 32.6% from 35.8% in Q2, so the guidance raise may rely on mix or cost timing that could reverse.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Home care platform reporting Q2 results and raising FY2026 revenue and Adjusted EBITDA guidance.

  • Jeff Shaner

    CEO quoted on momentum and the rationale for raising guidance.

  • Matt Buckhalter

    CFO quoted referencing acquisition and credit facility repricing.

Related articles

$AVAHHighAI 9/10

Why is Aveanna Healthcare stock surging today?

Aveanna Healthcare (AVAH) shares rose about 10.5% in pre-open after the company raised its 2026 revenue outlook to more than $2.68B from prior guidance of $2.63B to $2.65B. Aveanna reported Q2 adjusted EPS of $0.22 vs $0.17 expected, and revenue of $670.5M vs $638.6M expected, citing early contribution from its Family First Homecare acquisition.

$AVAHMed

Bain, KKR, KV Asia shortlisted for Malaysia’s Avisena Healthcare stake sale as valuation hits US$368 million: sources

Bain Capital, KKR and KV Asia have been shortlisted to buy a 20–25% minority stake in Malaysia’s Avisena Healthcare, valuing the company at about RM1.5 billion (US$368m), according to two sources. Binding bids are due by end-July. The stake is estimated at RM300–400m. KKR and Bain declined comment; Avisena and KV Asia did not respond.

$AXTIMed

AXT Inc. - 500 Beiträge pro Seite

AXT, Inc. (Nasdaq:AXTI) updated Q1 2018 guidance after Beijing air-quality rules forced mandatory factory shutdowns. Revenue was guided to $24.0m to $24.5m, down from prior $26m to $27m. On April 25, 2018, it reported Q1 revenue of $24.4m, gross margin 39.2%, and net income $2.9m, or $0.07 diluted share.

MedAI 8/10

Schaeffler improves profitability in first half of 2026

Schaeffler AG reported first-half 2026 results. Revenue was 11,667 million euros, flat vs 11,845 million euros prior year. EBIT before special items rose to 549 million euros (482 million). EBIT margin before special items was 4.7% (4.1%). Free cash flow before M&A was -300 million euros. Full-year guidance was confirmed: revenue 22.5-24.5 billion euros and EBIT margin 3.5-5.5%.

$BSLMedAI 8/10

BlueScope FY profit jumps over 100% on U.S., Asia strength

BlueScope reported annual underlying net profit after tax of A$851.2 million, up from A$420.8 million, citing stronger U.S. steel spreads and improved Southeast Asian operations. It forecast underlying EBIT for 1H 2027 of A$860 million to A$960 million. BlueScope declared a final dividend of 65 cents and a special dividend of 70 cents per share, and plans to return A$3 per share in FY2027.